New Real-World MAVENCLAD ® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients
Merck, a leading science and technology company, today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experienced a significant improvement in quality-of-life (QoL) scores after the first course of treatment in Year 1 with MAVENCLAD. Additionally, late-breaking real-world MAVENCLAD data evaluating long-term mobility and disability status suggested sustained benefit beyond the last treatment course and a reduced need for a wheelchair or ambulatory device among MAVENCLAD-treated patients. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
A new interim analysis from the open-label Phase IV CLARIFY-MS study demonstrated improvements in QoL measures in 426 patients with RMS early in the treatment course (Year 1). After completing half the recommended cumulative dose of MAVENCLAD over two years, improvements from baseline were observed for physical and mental health composite scores (nominal p<0.0001) as measured by the Quality of Life-54 questionnaire. Safety data were consistent with the safety profile seen in the MAVENCLAD clinical development program.
“Those living with MS know the effect of a treatment goes beyond what is shown in MRIs or in bloodwork. Many patients express that the impact on physical and mental well-being is just as important,” said Prof. Jeannette Lechner-Scott, PhD, FRACP, Senior Staff Specialist in the Department of Neurology and Conjoint Professor at the University of Newcastle, Australia. “The quality-of-life outcomes from the CLARIFY-MS study support that MAVENCLAD positively impacts these measures early in the treatment course.”
Also presented were late-breaking final data from the Phase IV CLASSIC-MS, a follow-up study, which showed that 90.0% of patients with RMS treated with cladribine tablets did not need to use a wheelchair or were not confined to bed (i.e., with an Expanded Disability Status Scale <7) after a median follow-up of 10.9 years (range 9.3-14.9). Additionally, 81.2% of cladribine tablets-treated patients did not require an ambulatory device. CLASSIC-MS investigated the long-term efficacy in 435 patients with RMS – 90.6% of whom were exposed to cladribine tablets during the CLARITY and CLARITY Extension trials. The study focused on long-term mobility and disability – two areas of importance as MS can cause problems with movement, balance and coordination that can worsen over time.
An independent study, presented by Prof. Adi Vaknin-Dembinsky, MD, PhD, Senior Neurologist, Hadassah Medical Center at the Hebrew University, Jerusalem, Israel, evaluated antibody response after a complete course of the Pfizer/BioNTech mRNA COVID-19 vaccine in healthy controls and patients with MS (untreated, or treated with MAVENCLAD or interferon beta-1a). Consistent with previously reported data, MAVENCLAD-treated patients, as well as those treated with interferon beta-1a, who received the Pfizer/BioNTech mRNA COVID-19 vaccine were found to mount a positive serology response (AU/mL >19), similar to that of healthy controls. Specifically, all patients with MS treated with MAVENCLAD (n=30) had a positive serology response against the spike protein two to three weeks after vaccination (mean=226.3±121.4). In the study, the shortest interval between vaccination and the last dose of MAVENCLAD was 12 weeks.
“The long-term MAVENCLAD outcomes presented at ECTRIMS 2021 suggest the potential to positively impact future mobility and disability status, supporting why MAVENCLAD should be considered a disease-modifying therapy of choice for appropriate adult patients living with RMS,” stated Danny Bar-Zohar, MD, Global Head of Development for the Healthcare business of Merck. “As new strains of COVID-19 push the pandemic onward and guidance recommends booster vaccinations, we are encouraged to have new data that continues to show MAVENCLAD-treated patients with RMS who received an mRNA COVID-19 vaccine have a similar antibody response to the general population.”
MAVENCLAD® is a short-course oral therapy that selectively and periodically targets lymphocytes thought to be integral to the pathological process of relapsing MS (RMS). In August 2017, the European Commission (EC) granted marketing authorization for MAVENCLAD® for the treatment of relapsing forms of multiple sclerosis (RMS) in the 28 countries of the European Union (EU) in addition to Norway, Liechtenstein and Iceland. MAVENCLAD® has since then been approved in over 80 countries, including Canada, Australia and the U.S. Refer to the respective prescribing information for further details.
The clinical development programme for cladribine tablets includes:
- The CLARITY (Cladribine Tablets Treating MS Orally) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients with RRMS.
- The CLARITY extension study: a Phase III placebo-controlled study following on from the CLARITY study, which evaluated the safety and exploratory efficacy of cladribine tablets over two additional years beyond the two-year CLARITY study, according to the treatment assignment scheme for years 3 and 4.
- The ORACLE MS (Oral Cladribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of cladribine tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).
- The ONWARD (Oral Cladribine Added ON to Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding cladribine tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.
- PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis) study: a long-term observational follow-up safety registry of MS patients who participated in cladribine tablets clinical studies.
In the two-year CLARITY study, the most commonly reported adverse event (AE) in patients treated with cladribine tablets was lymphopenia (26.7% with cladribine tablets and 1.8% for placebo). The incidence of infections was 48.3% with cladribine tablets and 42.5% with placebo, with 99.1% and 99.0% respectively rated mild-to-moderate by investigators. Adverse Events reported in other clinical studies were similar.
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by email at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science and EMD Electronics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
+49 151 1454 2694
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deel Raises $425M in Series D Funding to Continue Transforming the Future of Work18.10.2021 14:45:00 CEST | Press release
Deel, the remote hiring company shattering job barriers worldwide, announced today that it has raised $425 million in Series D funding, taking the total amount raised by the company to over $630 million. The latest funding round values the company at $5.5 billion. Deel has become the highest valued company in the global hiring, payments, and compliance space with this investment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005567/en/ Deel Interface (Graphic: Business Wire) This new funding round was led by US-based Coatue, with partners Rahul Kishore and Lucas Swisher leading the deal. Several new and existing investors also participated in this round, including Altimeter Capital, Andreessen Horowitz, the YC Continuity Fund, Spark Capital, Greenbay Ventures, Neo, and over 40 of the world’s leading operators. Since Deel’s inception in 2019, the team - growing from four to 400 employees - has been on a mission to make
William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today18.10.2021 14:30:00 CEST | Press release
Everbridge, Inc. (NASDAQ: EVBG) today announced the launch of its podcast Unlocking Resilience™: Global Leadership Seriesfeaturing William Shatner as its inaugural guest. The first-of-its-kind podcast features global influencers, government leaders, C-level executives and top healthcare experts as they discuss the confluence of leadership, technology and resilience at both the personal and organizational level. Topics will include overcoming personal challenges to create a life of resilience; effective strategies for building organizational resilience and business continuity in the face of critical events; and perspectives on the future of work, life and entertainment in a post-pandemic world, among other topics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005565/en/ William Shatner Launches Everbridge’s ‘Unlocking Resilience’ Global Leadership Podcast Series, Available Today (Graphic: Business Wire) The Unlocking R
Ferring to Present Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection and IBD at ACG 202118.10.2021 14:00:00 CEST | Press release
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced they will present data from two new retrospective analyses as part of American College of Gastroenterology’s Annual Scientific Meeting & Postgraduate Course (ACG 2021). The congress will take place in Las Vegas from October 22 – 27, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005060/en/ Eligibility criteria in CDI clinical trials often are narrowly defined, excluding broader patient populations. The first presentation will explore key health outcomes of RBX2660, an investigational microbiota-based live biotherapeutic for reduction of recurrent C. difficile infection (CDI), among patients in a real-world setting. The second analysis evaluates healthcare resource utilization and medical costs among Medicare patients with CDI with or without inflammatory bowel disease (IBD) as a comorbidity. Notably, one of the presentations has received The
Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes18.10.2021 13:30:00 CEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive Day 90 data for the first patient from the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D). This is the first demonstration of a patient with T1D achieving robust restoration of islet cell function from such a cell therapy. The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy. The patient achieved successful engraftment and demonstrated rapid and robust improvements in multiple measures, including increases in fasting and stimulated C-peptide, improvements in glycemic control, including HbA1c, and decreases in exogenous insulin requirement. VX-880 was generally well tolerated. “These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were ac
Industrial Flow Solutions™ Announces Deal to Acquire Clearwater Controls™ to Grow IoT Solutions for Wastewater Network Management, Increase Demand for Industry-Leading DERAGGER ™ +18.10.2021 13:06:00 CEST | Press release
Leading industrial pumping solutions provider Industrial Flow Solutions™, headquartered in New Haven, Conn., USA, announced today the agreement to acquire Clearwater Controls Ltd.™, based in Glasgow, Scotland. Clearwater Controls offers a broad line of wastewater solutions, beginning with its leading deragging intelligent systems to solve specific pumping problems, to more advanced monitoring technology to optimize and manage entire water networks. Terms of the acquisition were not disclosed. Clearwater Controls will retain its company name and brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005200/en/ Clearwater Controls' DERAGGER™ products offer intelligent efficiency and the end of ragging. Industrial Flow Solutions has announced a deal to acquire Clearwater Controls to grow IoT solutions for wastewater network management. Clearwater Controls offers a broad line of wastewater solutions, beginning with its lead
ThreatConnect Releases Risk Quantifier™ 6.0 — Driving Continued Innovation in Cyber Risk Quantification18.10.2021 12:30:00 CEST | Press release
ThreatConnect Inc.®, the leader in reducing complexity and enabling better decision making in cybersecurity, today released ThreatConnect Risk Quantifier™ 6.0 (RQ 6.0), continuing its innovation in the emerging field of cyber risk quantification. ThreatConnect Risk Quantifier™ (RQ) enables companies to see the financial risks they face from cyber attacks and also prioritize investments that provide the best ROI. RQ’s calculations are informed by your internal environment, threat intelligence, vulnerability management, operations and response data found within ThreatConnect and other integrations. RQ is distinctly different from other approaches offered in the market as it focuses on automation and data integration, and delivers value in days and weeks as opposed to months and years. With RQ 6.0 organizations that are looking at financial cyber risk quantification will have the option of leveraging full FAIR scenario’s, using semi-automated FAIR scenario’s, and full automation in one pl
Technology Innovation Institute’s Directed Energy Research Centre becomes First-in-Region to Replicate Electromagnetic Pulses from High-altitude Nuclear Reaction18.10.2021 11:28:00 CEST | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Centre (DERC) has become the first such entity in the region capable of reproducing the high-altitude electromagnetic pulses (HEMP) generated during nuclear reaction in high altitudes at its electromagnetic compatibility (EMC) labs. The Nuclear Electromagnetic Pulse Simulator offers critical infrastructures, service providers, and research institutions in the UAE and wider GCC region greater autonomy when it comes to testing - a function that needed to earlier be outsourced abroad. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005404/en/ Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (Photo: AETOSWire) DERC’s EMC labs comprise a modular semi-anechoic chamber that enables testing to evaluate susceptibility of electronics to